Neuralink's New Breakthrough: ALS Patient Achieves Autonomous Robotic Arm Control via Brain-Computer Interface
Release time:
2025-10-14
On October 12, Elon Musk’s brain-computer interface company Neuralink announced a major technical advancement: a patient with amyotrophic lateral sclerosis (ALS, commonly known as "frozen disease") successfully controlled a robotic arm using only their thoughts to complete multiple daily tasks via Neuralink’s system. This marks a critical leap for brain-computer interfaces, transitioning from digital interaction to physical control.
Demonstration videos of the patient, Nick Wray, show that the N1 chip implanted in his brain can decode neural signals in real time, wirelessly convert them into Bluetooth commands, and precisely drive the robotic arm to perform actions such as grasping a cup to drink, opening a refrigerator to retrieve items, heating food in a microwave, and putting on a hat. These seemingly "ordinary" tasks—taken for granted by those with severe mobility limitations—represent a significant milestone in regaining control over daily life. Additionally, Wray set a record in a dexterity test for stroke patients, moving 39 cylinders in five minutes. He also used the interface to control an electric wheelchair for the first time and completed a challenge he called an "incredible trick shot" (a related video will be released later).
This achievement stems from Neuralink’s "CONVOY" clinical study, approved by the U.S. Food and Drug Administration (FDA), which aims to test the effectiveness of brain-computer interfaces in assisting patients with daily tasks. Wray is the eighth participant to receive this experimental implant. Neuralink launched its first U.S. human trials in 2024, having previously addressed safety concerns raised by the FDA in 2022 through technical improvements to secure approval.
Notably, the first implant recipient, Noland Arbaugh, previously demonstrated digital interaction capabilities, including controlling a cursor and playing video games with his thoughts. Although a fault occurred where 85% of the fine wires in his device detached, Neuralink quickly optimized signal interpretation via a software update, maintaining the device’s effectiveness.
The N1 chip is the core of this breakthrough. About the size of a 10-pence coin, this implant contains 128 wires thinner than human hair, connected to approximately 1,000 electrodes. It directly reads signals from the brain’s motor cortex, converting neural activity into precise digital commands.
From controlling computers to operating robotic arms, Neuralink is expanding the application of brain-computer interfaces from the digital realm to the physical world. For patients with limited mobility—such as those with ALS or paralysis—this technology not only offers the possibility of "moving again" but also carries the hope of restoring dignity in life. As clinical trials progress, brain-computer interfaces may drive more profound transformations in neurorehabilitation.
Latest developments
Yinfeng Foundation Honored as "2025 Public Welfare Donor" by Jinan Red Cross
Looking ahead, Yinfeng Foundation will use this recognition as an opportunity to further deepen its strategic collaboration with the Jinan Red Cross, expand cooperation in areas such as life health and emergency response, and continue to empower efforts to accelerate the construction of a "new, strong, excellent, rich, beautiful, and high-quality" modern socialist strong capital city, contributing even more Yinfeng strength to this endeavor.
The team successfully developed the CryoSIM platform, an intelligent microfluidics and deep learning-integrated system. This platform deeply integrates core technologies of deep learning and microfluidics to enable high-throughput, high-precision automated analysis of oocyte membrane permeability. It provides a novel technological tool for optimizing and advancing the clinical translation of oocyte cryopreservation techniques. Additionally, it offers an innovative practical paradigm for the application of artificial intelligence in low-temperature biomedicine and reproductive medicine.
Public Welfare Partnership: A Special Letter from the Jinan Red Cross
On the afternoon of January 30, 2026, the Jinan Red Cross presented a letter of special significance to the Shandong Yinfeng Life Science Public Welfare Foundation (hereinafter referred to as the Yinfeng Foundation).
World’s First Achievement Highlights Brand Leadership
In the future, Yinfeng Life Science Research Institute will continue to uphold its mission of "Dedicated to Medical Technology, Safeguarding Human Health." It will empower brand building with more original and pioneering scientific and technological achievements, contributing wisdom and strength to Shandong's goal of building a national regional innovation hub and promoting Chinese brands on the global stage.
Global First Ovarian Tissue Dual Activation Technology Debuts at 2025 Jinan Achievements Conference
Currently, the ovarian tissue dual activation technology has been successfully applied in clinical practice at Beijing University of Chinese Medicine Shenzhen (Longgang) Hospital, having treated over 400 patients with a treatment success rate of 70%. Over the next three years, Shandong Yinfeng Life Science Research Institute plans to use Jinan as a center to gradually expand the transformation and application of this technological achievement nationwide.
According to the latest announcement from the International Society of Cryobiology, Professor Xu Yi from the School of Health Science and Engineering at the University of Shanghai for Science and Technology, and a member of the Yinfeng Cryomedicine Expert Committee, has been elected as a Board Governor of the Society for a three-year term (2026–2028). The election was conducted through a democratic vote by all members worldwide, with three new Board Governors elected. Professor Xu Yi is the only scholar from Asia elected to the Society’s Board of Governors this time and the third elected scholar from mainland China in the Society’s 60-year history.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155515
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
